The Circulating Methylome in Childhood-Onset Inflammatory Bowel Disease
By
Alexandra Noble
Alex Adams
Jan Nowak
Guo Cheng
Komal Nayak
Aisling Quinn
Mark Kristiansen
Rahul Kalla
Nicholas T Ventham
Federica Giachero
Chamara Jayamanne
Richard Hansen
Georgina L Hold
Emad El-Omar
Nicholas M Croft
David Wilson
R Mark Beattie
James J Ashton
Matthias Zilbauer
Sarah Ennis
Holm H Uhlig
Jack Satsangi
October 4, 2024
Clinical Scorecard: Circulating Methylation Patterns in Pediatric Inflammatory Bowel Disease
At a Glance
Category Detail
Condition Pediatric Inflammatory Bowel Disease (IBD), including Crohn’s disease (CD) and ulcerative colitis (UC) Key Mechanisms Genetic susceptibility (~20% variance), epigenetic alterations (DNA methylation), environmental influences (passive smoking, nutrition, microbiome), and accelerated epigenetic aging Target Population Children under 18 years diagnosed with IBD Care Setting Pediatric gastroenterology clinics and research cohorts in the UK and North America
Key Highlights
A validated 4-probe methylation biomarker panel (RPS6KA2, VMP1, CFI, ARHGEF3) shows high diagnostic accuracy (AUC 0.90-0.94) for pediatric IBD. Significant epigenetic age acceleration is observed at diagnosis, especially in Crohn’s disease patients. Passive smoking exposure is associated with the development of ulcerative colitis rather than Crohn’s disease. Guideline-Based Recommendations
Diagnosis
Use of epigenome-wide methylation profiling as a diagnostic biomarker adjunct in pediatric IBD. Diagnosis based on modified Porto criteria for pediatric IBD. Management
Early identification of disease progression risk via methylation biomarkers to guide treatment escalation decisions. Consideration of environmental exposures such as passive smoking in disease management. Monitoring & Follow-up
Monitor epigenetic age acceleration as a potential marker of disease activity or progression. Follow-up within 18 months to assess need for surgery, biological therapy, or steroid courses. Risks
Environmental factors including passive smoking may influence disease subtype development. Genetic and epigenetic interactions contribute to disease variance and progression risk. Patient & Prescribing Data
Children diagnosed with Crohn’s disease or ulcerative colitis under 18 years
Methylation biomarkers outperform traditional blood markers like CRP in diagnosis; early treatment escalation may be guided by biomarker profiles.
Clinical Best Practices
Incorporate epigenetic biomarker panels alongside clinical criteria for accurate pediatric IBD diagnosis. Assess environmental exposures, particularly passive smoking, during patient history taking. Use longitudinal monitoring of methylation patterns to inform prognosis and therapeutic decisions. Apply genome-wide and epigenome-wide association studies to understand individual disease mechanisms. References
